Revefenacin (Theravance Biopharma/Mylan) is a long-acting muscarinic antagonist (LAMA) that will join a very crowded COPD market. The drug will be in direct competition with the gold-standard therapy Spiriva (tiotropium; Boehringer Ingelheim), as well as a host of other LAMA therapies that are available for the treatment of COPD. Revefenacin’s positive clinical trial data may help its uptake, but its late entry to the COPD market and its formulation as a nebulized therapy will significantly limit its potential.
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.